



**Richard F. Pops**  
**Chief Executive Officer**  
**Alkermes, Inc.**

Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio of more than 20 commercial products. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

**Committee on Energy and Commerce  
U.S. House of Representatives**

Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)

<b>1. Your Name:</b> Richard F. Pops		
<b>2. Are you testifying on behalf of the Federal, or a State or local government entity?</b>	Yes	No X
<b>3. Are you testifying on behalf of an entity that is not a government entity?</b>	Yes X	No
<b>4. Other than yourself, please list which entity or entities you are representing:</b> Alkermes, Inc.		
<b>5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011:</b>		
<ul style="list-style-type: none"> <li>• One grant from NIDA in the form of reimbursement of R&amp;D expenses, and related NIDA – Clinical Trial Agreement – ALKS33-buprenorphine for cocaine addiction – 11/19/2009</li> <li>• NIDA – Medications Development Program – Agreement for submitting compounds for preclinical, pharmacological, pharmacokinetic and toxicology evaluation; 2/10/2011</li> <li>• NIDA – Confidentiality Agreements –various dates</li> <li>• NIDA – Investigator Initiated Study Agreement – Cocaine Use Reduction with buprenorphine; 9/8/2011</li> <li>• NIDA – Investigator Initiated Study Agreement – Accelerated Development of Addictive Pharmacotherapy Treatment for Methamphetamine Use Disorder; 10/25/2013</li> <li>• NIDA – Investigator Initiated Study Agreement – Comparing Treatment for HIV-positive Opioid and Alcohol Users in an Integrated Care Effectiveness Study; 4/22/2014</li> <li>• VA – confidentiality agreements – various facilities – related to ALK3831-401 clinical trial</li>   <li>• Agreements that pharmaceutical companies have in place with the federal government as a precondition to making available their products to federal healthcare beneficiaries and receiving federal coverage for such products, including the following: <ul style="list-style-type: none"> <li>○ Pharmaceutical Pricing Agreement between Secretary of HHS and Alkermes, Inc.</li> <li>○ Rebate Agreement between Secretary of HHS and Alkermes, Inc.</li> <li>○ Pharmaceutical Pricing Agreement between Secretary of Veterans Affairs and Alkermes, Inc.</li> <li>○ Medicare Coverage Gap Discount Program Agreement between Secretary of HHS and Alkermes, Inc.</li> <li>○ Master Agreement between Secretary of Veterans Affairs and Alkermes, Inc.</li> </ul> </li> </ul>		

**6. If your answer to the question in item 3 in this form is “yes,” please describe your position or representational capacity with the entity or entities you are representing:**

Chief Executive Officer

**7. If your answer to the question in item 3 is “yes,” do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?**

Yes

No  
X

**8. If the answer to the question in item 3 is “yes,” please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:**

None

**9. Please attach your curriculum vitae to your completed disclosure form.**

Signature: \_\_\_\_\_



Date: July 9, 2014